Insilico Medicine (03696.HK), a clinical-stage, generative AI-driven drug discovery company, today announced the nomination of ISM6200 as a potent, potentially best-in-class preclinical candidate (PCC) targeting NR3C1, for the treatment of ovarian cancer, Hypercortisolism (Cushing’s Syndrome), and other disorders related to excess cortisol including obesity. The process was empowered by Chemistry42, the generative chemistry engine affiliated to Insilico’s Pharma.AI, as well as the specialized applications across the molecule discovery and optimization cycle. 

B-cell acute lymphoblastic leukaemia is the most common form of childhood cancer. In this type of cancer, which affects blood cells, one of the most common abnormalities is the presence of cells with an excess of chromosomes (hyperdiploidy), a condition that leads to chromosomal instability. Now, a study published in Cell Reports reveals that this chromosomal instability caused by hyperdiploidy reduces the proliferation of the affected cells, delays their differentiation and allows some to persist as rare, long-lived clones in the bone marrow, but without triggering leukaemia.

A hard-to-treat form of cervical cancer may have a newly exposed weakness. 

Antibody therapies have been used to treat diseases for nearly two decades, but their association with harmful immune reactions, including anaphylaxis, remains unclear. Researchers from Chiba University examined how antibodies interact with Fcγ receptors in tumor-bearing mouse models and found that strong Fcγ receptor binding was associated with higher antidrug antibody levels and anaphylaxis, with tumor-associated myeloid cells implicated in this process. These findings may help guide the development of safer antibody therapies.

A randomized trial conducted by the Alliance for Clinical Trials in Oncology with support from the National Cancer Institute has found that duloxetine, a medication commonly used to treat chronic pain and psychiatric conditions, does not prevent nerve damage caused by chemotherapy in patients with colorectal cancer. The primary analysis of Alliance A221805 was published in JCO Oncology Advances.

A study led by Qun-Ying Lei shows that PGG inhibits the MAT2A enzyme activity while simultaneously promoting its degradation. This unique dual-action induces pyroptosis and enhances antitumor immunity, presenting a promising new strategy for cancer immunotherapy.

New single-cell technology reveals a critical blind spot in how scientists track immune activity. CIPHER-seq captures RNA and protein together, exposing real-time immune signals missed by standard methods—an advance that could improve immunotherapy design and prediction of patient response.

A $1 million Research Scholar Grant from the American Cancer Society will help a multi-institution team led by Dr. Bishoy Faltas, associate professor of medicine at Weill Cornell Medicine, to develop new therapy combinations for hard-to-treat urinary tract cancers.